The following article features coverage from the American Urological Association (AUA) 2019 meeting. Click here to read more of Renal & Urology News’ conference coverage.

CHICAGO—Adjuvant single-dose upper urinary tract instillation of mitomycin C (ASDM) is safe and appears to decrease the risk of local recurrence of upper tract urothelial carcinoma (UTUC), investigators reported at the 2019 American Urological Association annual meeting.

Andrea Gallioli, MD, of Autonoma University of Barcelona in Barcelona, Spain, and colleagues studied 32 patients who underwent therapeutic ureteroscopy (URS) for UTUC. Of these, 15 received ASDM within 24 hours after the procedure. ASDM consisted of 40 mg/40 mL mitomycin C diluted in 20 mL saline administered over 1 hour. The remaining 17 patients served as controls. The groups were similar with respect to tumor grade and dimensions, number of lesions and other characteristics. The median follow-up was 18 months.

Bladder, local, and local/bladder recurrence developed in 23.1%, 20%, and 26.7% of patients in the ASDM group, respectively, compared with 26.7%, 35.3%, 52.9% of the control group, the investigators reported in a poster presentation. On multivariable analysis, ASDM was significantly associated with an 87% decreased risk of urothelial recurrence.

“The immediate single-dose upper urinary tract instillation of mitomycin C after therapeutic URS is safe and feasible,” the authors wrote. “In appears to reduce the risk of recurrence in [treatment] naïve patients affected by low-grade UTUC without concomitant bladder tumour. Therefore, its use should be encouraged.”

Read more of Renal & Urology News’ coverage of the AUA 2019 meeting by visiting the conference page.

Reference

Gallioli A, Breda A, Vila-Reyes H, et al. Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: preliminary results. Presented at the 2019 American Urological Association annual meeting. Abstract MP50-04.